WO2008025830A3 - Pharmaceutical and sunscreen compositions comprising caspase-14 - Google Patents

Pharmaceutical and sunscreen compositions comprising caspase-14 Download PDF

Info

Publication number
WO2008025830A3
WO2008025830A3 PCT/EP2007/059069 EP2007059069W WO2008025830A3 WO 2008025830 A3 WO2008025830 A3 WO 2008025830A3 EP 2007059069 W EP2007059069 W EP 2007059069W WO 2008025830 A3 WO2008025830 A3 WO 2008025830A3
Authority
WO
WIPO (PCT)
Prior art keywords
caspase
sunscreen compositions
pharmaceutical
compositions
sunscreen
Prior art date
Application number
PCT/EP2007/059069
Other languages
French (fr)
Other versions
WO2008025830A2 (en
Inventor
Wim Declercq
Geertrui Denecker
Peter Vandenabeele
Original Assignee
Vib Vzw
Univ Gent
Wim Declercq
Geertrui Denecker
Peter Vandenabeele
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Univ Gent, Wim Declercq, Geertrui Denecker, Peter Vandenabeele filed Critical Vib Vzw
Priority to AU2007291199A priority Critical patent/AU2007291199A1/en
Priority to EP07803078A priority patent/EP2061500A2/en
Priority to CA002661668A priority patent/CA2661668A1/en
Publication of WO2008025830A2 publication Critical patent/WO2008025830A2/en
Publication of WO2008025830A3 publication Critical patent/WO2008025830A3/en
Priority to IL197273A priority patent/IL197273A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Abstract

The present invention relates to the field of sunscreen compositions for preventing or treating the harmful effects of solar radiation in skin. More particularly the invention provides sunscreen compositions comprising caspase-14 as an ingredient.
PCT/EP2007/059069 2006-09-01 2007-08-30 Pharmaceutical and sunscreen compositions comprising caspase-14 WO2008025830A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2007291199A AU2007291199A1 (en) 2006-09-01 2007-08-30 Pharmaceutical and sunscreen compositions comprising caspase-14
EP07803078A EP2061500A2 (en) 2006-09-01 2007-08-30 Pharmaceutical and sunscreen compositions comprising caspase-14
CA002661668A CA2661668A1 (en) 2006-09-01 2007-08-30 Sunscreen compositions
IL197273A IL197273A0 (en) 2006-09-01 2009-02-26 Pharmaceutical and sunscreen compositions comprising caspase-14

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06119971.7 2006-09-01
EP06119971 2006-09-01
EP06126387 2006-12-18
EP06126387.7 2006-12-18

Publications (2)

Publication Number Publication Date
WO2008025830A2 WO2008025830A2 (en) 2008-03-06
WO2008025830A3 true WO2008025830A3 (en) 2008-05-02

Family

ID=38983406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/059069 WO2008025830A2 (en) 2006-09-01 2007-08-30 Pharmaceutical and sunscreen compositions comprising caspase-14

Country Status (5)

Country Link
EP (1) EP2061500A2 (en)
AU (1) AU2007291199A1 (en)
CA (1) CA2661668A1 (en)
IL (1) IL197273A0 (en)
WO (1) WO2008025830A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942231B1 (en) 2009-02-19 2015-03-20 Lfb Biotechnologies NUCLEIC ACIDS BINDING SPECIFICALLY TO HUMAN VII / VIIA FACTOR, AND USES THEREOF
FR2948664B1 (en) 2009-07-31 2013-11-01 Lfb Biotechnologies PROCESS FOR THE PURIFICATION OF GLA DOMAIN COAGULATION PROTEINS
FR2948665B1 (en) 2009-07-31 2011-09-23 Lfb Biotechnologies PROCESS FOR THE PURIFICATION OF ACTIVE GLA DOMAINE COAGULATION PROTEINS
FR2956115B1 (en) 2010-02-05 2012-04-06 Isp Investments Inc NOVEL CASPASE-14 ACTIVATOR PEPTIDES AND COMPOSITIONS COMPRISING THE SAME
US8383167B2 (en) 2011-03-08 2013-02-26 Elc Management, Llc Method for cosmetically treating caspase-14 deficiency
FR2983212A1 (en) 2011-11-28 2013-05-31 Lfb Biotechnologies ANTI-FH APTAMERS, PROCESS FOR OBTAINING THEM AND USES THEREOF
FR2987743B1 (en) 2012-03-12 2016-03-18 Isp Investments Inc COSMETIC USE OF OAT EXTRACT AS ACTIVATOR OF CASPACE-14
FR3011250A1 (en) 2013-09-30 2015-04-03 Lab Francais Du Fractionnement NUCLEIC ACIDS BINDING SPECIFICALLY TO HUMAN IX / IXA FACTOR, AND USES

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999023106A1 (en) * 1997-10-30 1999-05-14 Human Genome Sciences, Inc. Caspase-14 polypeptides
WO2000004169A1 (en) * 1998-07-17 2000-01-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw New caspase homologue
WO2001034183A2 (en) * 1999-11-10 2001-05-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
WO2001081595A2 (en) * 2000-04-27 2001-11-01 Knoll Gmbh Human caspase-14 compositions
WO2002095358A2 (en) * 2001-05-18 2002-11-28 Spectrx, Inc. System and method for monitoring or treating a health condition
WO2004053097A2 (en) * 2002-12-10 2004-06-24 Medical College Of Georgia Research Institute, Inc. Chemopreventive and therapeutic aspects of polyphenolic compositions and assays

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999023106A1 (en) * 1997-10-30 1999-05-14 Human Genome Sciences, Inc. Caspase-14 polypeptides
WO2000004169A1 (en) * 1998-07-17 2000-01-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw New caspase homologue
WO2001034183A2 (en) * 1999-11-10 2001-05-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
WO2001081595A2 (en) * 2000-04-27 2001-11-01 Knoll Gmbh Human caspase-14 compositions
WO2002095358A2 (en) * 2001-05-18 2002-11-28 Spectrx, Inc. System and method for monitoring or treating a health condition
WO2004053097A2 (en) * 2002-12-10 2004-06-24 Medical College Of Georgia Research Institute, Inc. Chemopreventive and therapeutic aspects of polyphenolic compositions and assays

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DENECKER G ET AL: "Caspase-14 protects against epidermal UVB photo-damage and water loss", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 127, no. Suppl. 1, April 2007 (2007-04-01), & 68TH ANNUAL MEETING OF THE SOCIETY-FOR-INVESTIGATIVE-DERMATOLOGY; LOS ANGELES, CA, USA; MAY 09 -12, 2007, pages S71, XP009095833, ISSN: 0022-202X *
DENECKER GEERTRUI ET AL: "Caspase-14 protects against epidermal UVB photodamage and water loss.", NATURE CELL BIOLOGY JUN 2007, vol. 9, no. 6, June 2007 (2007-06-01), pages 666 - 674, XP009095022, ISSN: 1465-7392 *
LIPPENS SASKIA ET AL: "Vitamin D3 induces caspase-14 expression in psoriatic lesions and enhances caspase-14 processing in organotypic skin cultures.", THE AMERICAN JOURNAL OF PATHOLOGY SEP 2004, vol. 165, no. 3, September 2004 (2004-09-01), pages 833 - 841, XP009095852, ISSN: 0002-9440 *
WALSH D S ET AL: "Psoriasis is characterized by altered epidermal expression of caspase 14, a novel regulator of keratinocyte terminal differentiation and barrier formation", JOURNAL OF DERMATOLOGICAL SCIENCE, ELSEVIER SCIENCE PUBLISHERS, SHANNON, IR, vol. 37, no. 1, January 2005 (2005-01-01), pages 61 - 63, XP004689814, ISSN: 0923-1811 *

Also Published As

Publication number Publication date
AU2007291199A1 (en) 2008-03-06
EP2061500A2 (en) 2009-05-27
IL197273A0 (en) 2011-08-01
CA2661668A1 (en) 2008-03-06
WO2008025830A2 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
WO2008025830A3 (en) Pharmaceutical and sunscreen compositions comprising caspase-14
WO2007131677A8 (en) Use of ginsenosides and extracts containing them
EP2168570A3 (en) Extracts of isochrysis sp.
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
HK1133787A1 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2006075330A3 (en) Methods and pharmaceutical compositions useful for treating psoriasis
WO2009074735A3 (en) Use of a novel natural agent in cosmetic compositions
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2009101503A3 (en) Use of natural active substances in cosmetic or therapeutic compositions
EP1816996A4 (en) Methods and therapeutic compositions comprising plant extracts for the treatment of cancer
WO2010081032A3 (en) Steroidal compositions
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
AP2698A (en) Agrochemical formulation of plant protection active ingredients for improving the action and plant tolerance
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2013178965A3 (en) Active ingredients activating mitophagy in skin cells and use of same for improving skin condition
PL2465493T3 (en) Topical compositions for the prevention and treatment of irritation of mucous cells
WO2011051633A3 (en) Use of a punica granatum extract to fight against the whitening of the hair
WO2010085091A3 (en) Pharmaceutical composition for preventing or treating hepatitis c, comprising the roots extract of platycodon grandiflorum or platycodon grandiflorum saponin components
EP2142549A4 (en) Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient
WO2009093104A3 (en) Use of transesterified olive oil in the cosmetic field
WO2008031940A3 (en) Xanthoxyline-based composition and cosmetic use thereof
WO2014043230A3 (en) Formulations comprising idebenone, n-acetyl-s-farnesyl-l-cysteine and ergothioneine and uses thereof
WO2012024399A3 (en) Compositions comprising paulownin and/or paulownia extracts and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07803078

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2661668

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 197273

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007291199

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007803078

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2188/DELNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007291199

Country of ref document: AU

Date of ref document: 20070830

Kind code of ref document: A